利拉鲁肽是一种GLP - 1受体激动剂，这类药可在用餐后促使胰腺分泌更多的胰岛素。
Victoza is in a class of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists that help the pancreas make more insulin after eating a meal.
而VPAC1激动剂在体重、血糖、糖耐量、胰岛素浓度及内脏净重等方面的治疗效果更为明显。
VPAC1 agonist displayed more effective effects than VIP on body weight, plasma glucose, glucose tolerance, plasma insulin, the weight of viscera.
而VPAC1激动剂在体重、血糖、糖耐量、胰岛素浓度及内脏净重等方面的治疗效果更为明显。
VPAC1 agonist displayed more effective effects than VIP on body weight, plasma glucose, glucose tolerance, plasma insulin, the weight of viscera.
应用推荐